



## Verastem Announces Annual Research and Development Day and Webcast

June 18, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 18, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the Company will host its annual Research and Development Day on Thursday, July 10, 2014 from 12:30 – 4:00pm ET at The Hudson Theatre at the Millennium Broadway Hotel in New York City.

The Company will provide updates regarding its research and development efforts and will host presentations by five key opinion leaders. The Company will present clinical data, anticipated milestones and upcoming plans for its programs targeting cancer stem cells. Lunch will be served. Please RSVP to [verastem@argotpartners.com](mailto:verastem@argotpartners.com).

**Title:** Verastem Research and Development Day 2014

**Date:** Thursday, July 10, 2014 at 12:30pm ET

**Location:** The Hudson Theatre at the Millennium Broadway Hotel, 145 West 44th Street, New York, NY

**Webcast:** <http://bit.ly/1IJM20T>

**Conference Call Dial-in (U.S.):** 866-906-7447

**Conference Call Dial-in (International):** 617-939-0999

**Conference Call Passcode:** 5946305

**RSVP:** [Verastem@argotpartners.com](mailto:Verastem@argotpartners.com)

Guest speakers scheduled to present include:

**José Baselga, M.D., Ph.D.**

*Physician in Chief, Memorial Sloan-Kettering Cancer Center*

Dr. Baselga's research includes the development of novel molecular targeted agents for cancer therapies, with special emphasis on breast cancer. His research in preclinical and early clinical development of therapies has helped develop a number of new targeted cancer-fighting agents. Dr. Baselga was previously Chief of Medical Oncology at Massachusetts General Hospital, Associate Chief of the MGH Cancer Center and chairman of the Medical Oncology Service and director of the Division of Medical Oncology, Hematology and Radiation Oncology at the Vall d'Hebron Institute of Oncology in Barcelona, Spain. Dr. Baselga completed a fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center where he remained as a faculty member of the Breast Medicine Service until 1996. Dr. Baselga has published more than 250 peer-reviewed articles and over 400 abstracts and book chapters in his career. He was previously the president of the European Society of Medical Oncology, served on the board of directors of the American Society of Clinical Oncology (ASCO) and is currently a member of the board of directors of the American Association for Cancer Research (AACR).

**Raphael Bueno, M.D.**

*Associate Chief, Division of Thoracic Surgery, Brigham & Women's Hospital*

Dr. Bueno is a Professor of Surgery at Harvard Medical School, as well as Associate Chief of Thoracic Surgery at Brigham and Women's Hospital. Dr. Bueno's research focuses on molecular analysis of malignant pleural mesothelioma and lung cancer, with a goal of improving diagnosis, prognosis, and treatment of the diseases. Dr. Bueno has done extensive research investigating peritoneal mesothelioma and pericardial mesothelioma at the cellular level in an effort to identify more effective treatment methods. Dr. Bueno completed his undergraduate and medical degrees at Harvard University. Dr. Bueno completed a fellowship in surgery at Brigham and Women's Hospital, as well as a residency in thoracic surgery at Massachusetts General Hospital. Dr. Bueno is board certified in surgery, surgical critical care, thoracic surgery, and has authored or co-authored more than 80 peer-reviewed journal articles. Dr. Bueno is the Primary Investigator on the Window of Opportunity Study of VS-6063 in participants with surgical resectable malignant pleural mesothelioma (NCT02004028).

**Professor Dean Fennell, Ph.D., FRCP**

*Chair of Thoracic Oncology, University of Leicester, UK*

Professor Fennell is a consultant physician and research scientist specializing in the treatment of lung cancer, and particularly mesothelioma for which he is internationally recognized. He is currently leading UK and international clinical trials of novel targeted therapies, and leads a translational research laboratory focused on identifying genetic predictors of novel drug effectiveness, a recognized priority area for improving outcomes in cancer research. Dr. Fennell has published over 50 peer reviewed research articles, reviews and book chapters on cancer pharmacology & clinical trials, is a regular reviewer for several international scientific journals and funding agencies and has been invited chair at national and international conferences. Professor Fennell is the incoming president of the International Mesothelioma Interest Group, member of the COMMAND International Steering Committee and coordinating investigator for COMMAND in the UK.

**Mary Hesdorffer, N.P.**

*Executive Director, Mesothelioma Applied Research Foundation*

Ms. Hesdorffer is a nurse practitioner by training, who, for over 16 years has treated mesothelioma patients in a clinical setting. Ms. Hesdorffer has published her own research in peer-reviewed journals and is a medical professional well-known and highly regarded by mesothelioma doctors and scientists. Ms. Hesdorffer has expertise in the development and implementation of clinical trials and has lectured nationally on topics pertaining to mesothelioma with particular emphasis on clinical trials as well as symptom and disease management. Through her work at the Mesothelioma Applied Research Foundation, Ms. Hesdorffer has been a strong voice in urging increased transparency to the medical and legal issues surrounding mesothelioma with a strong emphasis on ethics. Ms. Hesdorffer received both her undergraduate and Masters of Science degrees from the College of New Rochelle in New York.

**Manish R. Patel, M.D.**

*Associate Director of Research, Florida Cancer Specialists & Research Institute*

Dr. Patel oversees the treatment of cancer patients in Phase 1 clinical trials. In addition to his work at the Florida Cancer Specialists & Research Institute, Dr. Patel also serves as the Associate Director of Drug Development for the Sarah Cannon Research Institute, one of the nation's largest community-based clinical trial organizations. Dr. Patel is Board Certified in Medical Oncology, Hematology, and Internal Medicine. Dr. Patel completed his residency in Internal Medicine at Vanderbilt University Medical Center and his fellowship in Hematology/Oncology at the H. Lee Moffitt Cancer Center in Tampa. Dr. Patel received his undergraduate degree from the University of Florida and his M.D. from the University of Miami. Dr. Patel is an investigator on the Phase 1/1b study of paclitaxel in combination with VS-6063 in patients with advanced ovarian cancer (NCT01778803).

A replay of the webcast will be archived for 90 days following the presentation date.

**Replay webcast:** <http://bit.ly/1JMJ20T>

**Replay Dial-in (U.S.):** 888-799-6166

**Replay Dial-in (International):** 857-288-2550

**Replay Passcode:** 5946305

**About Verastem, Inc.**

Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit [www.verastem.com](http://www.verastem.com).

**Forward-looking statements:**

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

Source: Verastem, Inc.

**Verastem, Inc.**

Brian Sullivan, 617-252-9314

[bsullivan@verastem.com](mailto:bsullivan@verastem.com)